دورية أكاديمية
أعرض في EDS

Calreticulin Expression in Human Carcinomas: A Systematic Review and Meta-Analysis.

التفاصيل البيبلوغرافية
العنوان: Calreticulin Expression in Human Carcinomas: A Systematic Review and Meta-Analysis.
المؤلفون: Paravani Palacon M; Department of Diagnosis and Surgery, São Paulo State University (UNESP), School of Dentistry, Araraquara, São Paulo, Brazil., Morandin Ferrisse T; Department of Dental Prothesis, São Paulo State University (UNESP), School of Dentistry, Araraquara, São Paulo, Brazil., De Oliveira Barbeiro C; Department of Diagnosis and Surgery, São Paulo State University (UNESP), School of Dentistry, Araraquara, São Paulo, Brazil., Maria Sgavioli Massucato E; Department of Diagnosis and Surgery, São Paulo State University (UNESP), School of Dentistry, Araraquara, São Paulo, Brazil., Bufalino A; Department of Diagnosis and Surgery, São Paulo State University (UNESP), School of Dentistry, Araraquara, São Paulo, Brazil.
المصدر: Asian Pacific journal of cancer prevention : APJCP [Asian Pac J Cancer Prev] 2023 Sep 01; Vol. 24 (9), pp. 2929-2940. Date of Electronic Publication: 2023 Sep 01.
نوع المنشور: Meta-Analysis; Systematic Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: Asian Pacific Organization for Cancer Prevention Country of Publication: Thailand NLM ID: 101130625 Publication Model: Electronic Cited Medium: Internet ISSN: 2476-762X (Electronic) Linking ISSN: 15137368 NLM ISO Abbreviation: Asian Pac J Cancer Prev Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Bangkok : Asian Pacific Organization for Cancer Prevention,
مواضيع طبية MeSH: Calreticulin* , Carcinoma*/pathology, Humans ; Lymph Nodes/pathology ; Lymphatic Metastasis/pathology
مستخلص: Objective: The present study performed a systematic review and meta-analysis of observational studies on whether calreticulin levels could represent a prognostic factor in carcinoma patients. Calreticulin (CRT) is a multifunctional protein in the endoplasmic reticulum that can play distinct roles in different cancers.
Methods: The search was performed in PubMed, Scopus, the Cochrane Library, Web of Science, Lilacs, Science Direct, Embase, Bireme, and SciELO databases. After a full-text evaluation, only 14 articles remained. The RoBANS tool assessed the risk of bias. The meta-analysis was performed with R software, and the odds ratio (OR) was the effect measure. The random effects model was chosen, and the quality of evidence was evaluated according to GRADE.
Result: The most frequent carcinomas were in the breasts and the colon. CRT expression varied according to carcinoma origin and type, but these diseases had a prevalence of high CRT levels, indicating tumor progression. The high CRT levels were associated with lymph node metastasis (OR = 3.06 [1.71; 5.48]/p = 0.0002/I2 = 0%). All included articles had a blinding bias.
Conclusion: High CRT levels may represent a prognostic factor for metastatic lymph nodes in carcinoma patients.
References: Oncoimmunology. 2014 Dec 13;3(9):e955691. (PMID: 25941621)
BMJ. 2015 Jan 02;350:g7647. (PMID: 25555855)
Curr Opin Cell Biol. 2011 Apr;23(2):157-66. (PMID: 21094034)
Immunol Lett. 2018 Jan;193:25-34. (PMID: 29175313)
Ann Intern Med. 2007 Oct 16;147(8):W163-94. (PMID: 17938389)
Clin Exp Immunol. 2010 May;160(2):215-22. (PMID: 20030668)
Cancer Immunol Immunother. 2020 Feb;69(2):315-324. (PMID: 31915854)
Asian Pac J Cancer Prev. 2015;16(14):5619-24. (PMID: 26320426)
World J Gastroenterol. 2010 May 21;16(19):2428-34. (PMID: 20480531)
Cell Mol Biol (Noisy-le-grand). 2018 May 15;64(6):1-3. (PMID: 29808792)
Tumour Biol. 2013 Apr;34(2):1177-88. (PMID: 23334957)
BMJ. 2020 Jan 21;368:l6802. (PMID: 31964641)
Hemasphere. 2020 Jan 15;4(1):e333. (PMID: 32382708)
Curr Protein Pept Sci. 2018 Feb 13;19(4):344-357. (PMID: 28079009)
Cancer Immunol Immunother. 2010 Mar;59(3):465-72. (PMID: 19756593)
Ann Clin Lab Sci. 2017 Aug;47(4):395-402. (PMID: 28801364)
BMC Health Serv Res. 2004 Dec 22;4(1):38. (PMID: 15615589)
Nat Rev Clin Oncol. 2021 Oct;18(10):663-672. (PMID: 34079102)
Biomed Res Int. 2015;2015:526524. (PMID: 25918716)
Horm Metab Res. 2012 Jul;44(8):639-43. (PMID: 22773372)
Int J Biol Sci. 2012;8(3):353-62. (PMID: 22393307)
Ann Surg Oncol. 2009 Feb;16(2):524-33. (PMID: 19050968)
Int J Lab Hematol. 2020 Apr;42(2):e76-e79. (PMID: 31693300)
J Mol Med (Berl). 2007 Aug;85(8):863-75. (PMID: 17318615)
Oral Oncol. 2013 Jun;49(6):534-41. (PMID: 23375593)
Cancer Immunol Immunother. 2012 Jun;61(6):855-64. (PMID: 22083347)
Oncol Lett. 2017 Jun;13(6):4857-4862. (PMID: 28599487)
Diagn Pathol. 2013 Apr 15;8:58. (PMID: 23587357)
Sci Rep. 2019 Jul 22;9(1):10558. (PMID: 31332222)
Int J Mol Sci. 2014 Feb 20;15(2):2916-28. (PMID: 24566135)
Mol Cell. 2020 Feb 20;77(4):748-760.e9. (PMID: 31785928)
Oncoimmunology. 2019 Jul 3;8(10):e1629780. (PMID: 31646075)
Cells. 2022 May 24;11(11):. (PMID: 35681417)
Nat Rev Cancer. 2012 Dec;12(12):860-75. (PMID: 23151605)
Syst Rev. 2016 Dec 5;5(1):210. (PMID: 27919275)
Cell Res. 2021 Jan;31(1):5-16. (PMID: 32733014)
Curr Protein Pept Sci. 2019;20(1):111-112. (PMID: 30444198)
J Biol Chem. 2018 Jun 22;293(25):9555-9569. (PMID: 29769311)
Gastroenterology. 2006 Jun;130(7):2010-22. (PMID: 16762624)
Oncoimmunology. 2019 Dec 28;9(1):1708126. (PMID: 32002304)
Hum Pathol. 2013 Dec;44(12):2677-83. (PMID: 24060004)
Aging (Albany NY). 2021 Feb 11;13(4):5607-5620. (PMID: 33591948)
Mod Pathol. 2010 Dec;23(12):1559-66. (PMID: 20834237)
J Cell Physiol. 2014 Jul;229(7):887-97. (PMID: 24264800)
فهرسة مساهمة: Keywords: Calreticulin; Carcinoma; Neoplasms; Prognosis; Systematic review
المشرفين على المادة: 0 (Calreticulin)
0 (CALR protein, human)
تواريخ الأحداث: Date Created: 20230929 Date Completed: 20231005 Latest Revision: 20240105
رمز التحديث: 20240105
مُعرف محوري في PubMed: PMC10762747
DOI: 10.31557/APJCP.2023.24.9.2929
PMID: 37774043
قاعدة البيانات: MEDLINE
الوصف
تدمد:2476-762X
DOI:10.31557/APJCP.2023.24.9.2929